Why daratumumab is effective in multiple myeloma - results from the CASTOR trial
The success of Phase III TOWER trial of blinatumomab in ALL
New aims and next steps for adult ALL induction therapy
Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
Importance of Bcl-2-targeted therapies
John Gribben et al.